title: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
abstract: BACKGROUND
  Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss.
  
  
  METHODS
  Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment.
  
  
  RESULTS
  One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck.
  
  
  CONCLUSIONS
  Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
authors.affiliation: Department of Gynecology, University Hospital of Giessen and Marburg, Marburg, Germany. hadji@med.uni-marburg.de
authors.forename: P
authors.initials: P
authors.lastname: Hadji
authors.forename: M
authors.initials: M
authors.lastname: Ziller
authors.forename: D G
authors.initials: DG
authors.lastname: Kieback
authors.forename: W
authors.initials: W
authors.lastname: Dornoff
authors.forename: H W
authors.initials: HW
authors.lastname: Tessen
authors.forename: T
authors.initials: T
authors.lastname: Menschik
authors.forename: J
authors.initials: J
authors.lastname: Kuck
authors.forename: F
authors.initials: F
authors.lastname: Melchert
authors.forename: A
authors.initials: A
authors.lastname: Hasenburg
mesh_terms: D000368:Aged; D000730:Androstadienes / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D011446:Prospective Studies; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D013629:Tamoxifen; C056516:exemestane